Last reviewed · How we verify
Dalteparin Injectable Solution
Dalteparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factor Xa and thrombin.
Dalteparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factor Xa and thrombin. Used for Venous thromboembolism prophylaxis, Treatment of deep vein thrombosis, Treatment of pulmonary embolism.
At a glance
| Generic name | Dalteparin Injectable Solution |
|---|---|
| Sponsor | Queen Mary University of London |
| Drug class | Low-molecular-weight heparin (LMWH) |
| Target | Antithrombin III (indirect target); Factor Xa and Thrombin (Factor IIa) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Dalteparin binds to and potentiates antithrombin III, a natural anticoagulant, leading to inactivation of activated factor X (Xa) and thrombin (factor IIa). This prevents the formation and extension of fibrin clots. Low-molecular-weight heparins like dalteparin have more predictable pharmacokinetics and longer half-lives than unfractionated heparin, allowing for subcutaneous dosing.
Approved indications
- Venous thromboembolism prophylaxis
- Treatment of deep vein thrombosis
- Treatment of pulmonary embolism
- Acute coronary syndrome
Common side effects
- Bleeding
- Thrombocytopenia
- Injection site hematoma
- Elevated transaminases
- Osteoporosis (with long-term use)
Key clinical trials
- Two Different Regimens of Bemiparin as a Thromboprophylaxis in Morbidly Obese Surgical Patients (NA)
- Thromboprophylaxis in Lower Limb Immobilisation (PHASE3)
- Comparison of 2 Low Molecular Weight Heparin as a Thromboprophylaxis Postpartum (NA)
- Edoxaban Steady-State PK/PD in Adults With Nephrotic Syndrome (NA)
- Enhanced Recovery After Surgery(ERAS) Following Gynaecological Oncology Surgery in a Tertiary Level Hospital (NA)
- A Dose-Response Controlled Trial of Bevifibatide for Acute Ischemic Stroke (PHASE2)
- Tinzaparin And Biomarkers After Neoadjuvant Treatment of Ovarian Cancer (PHASE2)
- Long-Term Innohep® Treatment Versus a Vitamin K Antagonist (Warfarin) for the Treatment of Venous Thromboembolism (VTE) in Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dalteparin Injectable Solution CI brief — competitive landscape report
- Dalteparin Injectable Solution updates RSS · CI watch RSS
- Queen Mary University of London portfolio CI